RASSF9抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08678(RASSF9 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08678(RASSF9 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The Ras association domain family (RASSF) member 9 (RASSF9) is a less characterized protein within the RASSF family, which is broadly implicated in tumor suppression, apoptosis, and cell cycle regulation. Unlike well-studied members like RASSF1A or RASSF2. RASSF9’s biological functions remain partially understood. It contains a Ras association (RA) domain, suggesting potential interactions with Ras-related GTPases, though its precise signaling mechanisms are unclear. Studies indicate RASSF9 may influence cell proliferation, differentiation, and tissue development, with roles in skin homeostasis and hair follicle regeneration reported in murine models. Its expression is tissue-specific, enriched in epithelial and immune cells, and dysregulation has been tentatively linked to cancers, though evidence remains limited.

RASSF9 antibodies are essential tools for investigating its expression patterns, subcellular localization, and interactions. These antibodies are typically validated for applications like Western blotting, immunohistochemistry, or immunofluorescence. Commercial RASSF9 antibodies are often raised against conserved regions, such as the N-terminal or RA domain, and may be polyclonal or monoclonal. Researchers must verify specificity through controls like knockout cell lines or siRNA-mediated knockdown. Challenges include cross-reactivity with other RASSF members due to sequence homology and limited commercial availability of high-quality reagents. Current research focuses on clarifying RASSF9’s role in diseases, particularly cancer and inflammatory conditions, leveraging these antibodies to explore its potential as a biomarker or therapeutic target. Further studies are needed to unravel its molecular pathways and clinical relevance.